Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 23-1169 (Fed. Cir. June 25, 2024)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Amarin Pharma, Inc., Amarin Pharmaceuticals Ire- land Limited, and Mochida Pharmaceutical Co., Ltd. (col- lectively, “Amarin”) appeal from a decision of the United States District Court for the District of Delaware granting Hikma Pharmaceuticals USA Inc.’s and Hikma Pharma- ceuticals PLC’s (collectively, “Hikma”) motion to dismiss Amarin’s complaint for failure to state a claim. Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., 578 F. Supp. 3d 642 (D. Del. 2022) (“Decision”).